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ABSTRACT 
Objectives: Sleep disturbance, pain, anxiety, depression and low energy/fatigue, the SPADE 
pentad, are the most prevalent and co-occurring symptoms in the general population and clinical 
practice. Co-occurrence of SPADE symptoms may produce additive impairment and negatively 
affect treatment response, potentially undermining patients’ health and functioning. The purpose 
of this paper is to determine: (1) prevalence and comorbidity (i.e., clustering) of SPADE 
symptoms; (2) internal reliability and construct validity of a composite SPADE symptom score 
derived from the Patient-Reported Outcomes Measurement Information System (PROMIS) 
measures; and (3) whether improvement in somatic symptom burden represented by a composite 
score predicted subsequent measures of functional status at 3 and 12 months follow-up. 
Methods: Secondary analysis of data from the Stepped Care to Optimize Pain care Effectiveness 
study, a randomized trial of a collaborative care intervention for Veterans with chronic pain. 
Results: Most patients had multiple SPADE symptoms; only 9.6% of patients were 
monosymptomatic. The composite PROMIS symptom score had good internal reliability 
(Cronbach’s alpha = 0.86) and construct validity and strongly correlated with multiple measures 
of functional status; improvement in the composite score significantly correlated with higher 
scores for five of six functional status outcomes. The standardized error of measurement for the 
raw composite score was 2.84, suggesting a 3-point difference in an individual’s composite score 
may be clinically meaningful.  
Discussion: Brief PROMIS measures may be useful in evaluating SPADE symptoms and overall 
symptom burden. Because symptom burden may predict functional status outcomes, better 
identification and management of comorbid symptoms may be warranted.  
Key Words: chronic pain; patient-centered outcomes research; primary care; psychometrics 
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INTRODUCTION 
More than half of all outpatient visits are attributed to physical symptoms, which 
translates to over 400 million outpatient visits annually.1 The complexity in symptom science 
research is burgeoning2 as the need to address symptom clusters in clinical practice has become 
increasingly evident.3, 4 Research to date suggests that symptoms may not be independent 
entities, but rather symptoms interacting synergistically.3, 4 Thus, co-occurring symptoms (i.e., 
symptom clusters) are a current research priority because they have a greater adverse impact on 
outcomes than individual symptoms alone.3 Sleep disturbance, pain, anxiety, depression, and low 
energy/fatigue (the SPADE pentad) comprise five of the most prevalent, chronic, disabling, and 
under-treated symptoms in both the general population5 and in clinical practice.5-10 Pain and 
depression co-occur with rates of 30-50%,11, 12 and a majority of patients seeking treatment for 
pain report sleep disturbance of a severity warranting attention; sleep disturbance can aggravate 
pain and inflammatory processes, reduce endogenous pain inhibitory responses, and increase 
emotional distress and reduce well-being.13 The co-occurrence of SPADE symptoms can produce 
an additive impairment, negatively affect treatment response, and undermine patients’ general 
health and physical functioning. Thus, focusing solely on one symptom, while ignoring other 
comorbid symptoms, may not be an optimal approach. Rather, targeting multiple symptoms may 
be preferable.14  
The Patient-Reported Outcomes Measurement Information System (PROMIS)2, 15 
establishes a national resource for highly reliable and precise measurement of patient-reported 
symptoms, functioning, and health-related quality of life in chronic disease.2, 15 These can be 
used as primary or secondary outcomes in research as well as clinical practice.16 There are 
PROMIS profiles with four-, six-, and eight-item scales to assess seven domains including 
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depression, anxiety, pain, fatigue, sleep, physical functioning, and social role satisfaction.15 
Consistent use of common, standardized measures across research studies will better position 
researchers and clinicians to ask and answer complex questions about the nature of individual 
symptoms and symptom clusters.  
In this paper, data is analyzed from a clinical trial involving primary care Veteran 
patients with chronic musculoskeletal pain. Specific aims were to determine: (1) the prevalence 
and comorbidity (i.e., clustering) of SPADE symptoms; (2) the internal reliability and construct 
validity of a composite SPADE symptom score derived from PROMIS measures; and (3) 
whether improvement in somatic symptom burden represented by a composite score predicted 
subsequent measures of functional status at 3 and 12 months follow-up. 
MATERIALS AND METHODS 
Design and Study Participants 
This was a secondary analysis of data from the Stepped Care to Optimize Pain care 
Effectiveness (SCOPE) study, a 12-month randomized controlled effectiveness trial of a telecare 
collaborative care intervention for primary care patients with chronic musculoskeletal pain. The 
study design and sample characteristics of the SCOPE trial have been described in detail 
elsewhere.17, 18 SCOPE participants were primary care patients aged 18 to 65 years enrolled from 
five general medicine clinics at a single Veterans Affairs (VA) medical center. Patients were 
eligible if they had pain meeting pre-specified criteria including: (a) musculoskeletal, defined as 
regional (joints, limbs, back, neck) or generalized (fibromyalgia or persistent widespread) pain; 
(b) moderately severe pain, defined as a Brief Pain Inventory intensity item score of 5 or higher 
for either “average” or “worst” pain in the past week (this threshold was selected since scores of 
4 to 6 on this 0-10 point scale represent moderate pain and selecting 5 allowed for some 
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regression to the mean); and (c) persistent (i.e., > 3 months) pain despite trying at least one 
analgesic medication. Excluded were patients who had a pending pain-related disability claim 
(because their motivation to improve during a trial may be less), dementia, schizophrenia, bipolar 
disorder, illicit drug use, active suicidal ideation, or an anticipated life expectancy of less than 12 
months. Letters were mailed to 940 patients with ICD-10 musculoskeletal pain codes, of whom 
311 expressed potential interest and were contacted by telephone. Among these, 10 refused the 
eligibility interview, 29 were ineligible, and 22 were eligible but not interested in participating.  
Thus, 250 patients were randomized to either a telecare intervention arm that optimized analgesic 
therapy or a usual care control arm. The study was approved by the university institutional 
review board and VA Medical Center research review committee.  
Measures 
As part of the SCOPE trial, study participants completed PROMIS four-item measures 
for each of the five SPADE symptoms (i.e., sleep, pain, anxiety, depression, and low 
energy/fatigue). Each of the four-item scales are part of the PROMIS-29 profile.15 Individual 
items for each of the five symptom scales use five response options (e.g., 1 = not at all to 5 = very 
much), with scale scores ranging from 4 to 20 and higher scores indicating worse symptom 
severity.15  Raw scores can be converted to T-scores (using conversion tables available at 
www.nihpromis.org)16 which are derived from item-response therapy and are standardized so 
that a scale score of 50 represents the mean of the general population, based on large-sample 
normative data.19 Each 10-point change represents one SD (e.g., a score of 60 is 1 SD worse and 
a score of 40 is 1 SD better than the general population mean). The advantages of the T-score are 
that the severity of different symptoms can be compared (e.g., a T-score of 60 for pain and 55 for 
fatigue would mean than an individual’s pain is relatively worse than their fatigue). 
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Several other measures completed by SCOPE participants were used to assess construct 
and predictive validity of the SPADE symptoms. Somatic symptom burden was assessed with 
the 14-item Patient Health Questionnaire (PHQ) somatization scale, which is identical to the 
PHQ-15 except for deletion of the infrequently endorsed sexual dysfunction item; the PHQ-15 is 
among the best validated and widely used measures of somatization.20, 21 Functional status was 
assessed with the SF-12 (which provides both Physical Component Summary and Mental 
Component Summary scores), plus additional items from the SF-36 to provide the general health 
and social functioning scores.22, 23 SF-12 and SF-36 scores range from 0 to 100 with lower scores 
representing worse health-related quality of life. Health-related disability days were assessed by 
asking patients for the total number of days, during the past 4 weeks, that they reduced their 
usual activities for one-half day or more because of physical health or emotional problems. 
Scores range from 0 to 28 days. Patients were also asked how effective they had been at their job 
during the past 2 weeks from 0% (“not at all effective”) to 100% (“completely effective”). These 
measures had high reliability in SCOPE as well as several previous trials.17, 24-25 
Statistical Analysis 
 Data were analyzed using SAS (version 9.1). PROMIS raw and T-scores were calculated 
for each of the five SPADE symptoms. Composite PROMIS SPADE raw and T-scores were 
calculated by taking the sum of the individual symptom scale scores and dividing by 5. For 
operational purposes, a T-score ≥ 55 was considered a clinically significant threshold since this 
represents a score that is ≥ 0.5 SD worse than the general population, which in turn represents a 
moderate effect size.26 Internal reliability of the composite score was estimated by Cronbach’s 
alpha. The standard error of measurement (SEM) for the raw composite SPADE score was 
calculated as the SD of the baseline score for that measure, multiplied by the square root of one 
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minus the Cronbach’s alpha.27 The SEM can be regarded as the SD of a person’s individual 
score, and either 1 or 2 SEMs have been considered one approach to estimating the minimally 
important difference for a scale.28, 29 
Descriptive statistics were used to evaluate the prevalence and co-occurrence of SPADE 
symptoms as well as associations with sociodemographic factors. Construct validity was 
examined by determining the correlations of the PROMIS individual and composite symptom 
scale scores with measures of somatization and functional status. Predictive validity was 
examined by using linear mixed effects models for repeated measures (MMRM) analysis to 
determine if antecedent changes in somatic symptom burden represented by the composite 
PROMIS SPADE score predicted subsequent measures of functional status at 3 and 12 months 
follow-up (Figure 1). MMRM models were adjusted for age, sex, medical comorbidity, and 
socioeconomic status (SES). Medical comorbidity (scored 0 to 9) was assessed using a checklist 
of nine common medical conditions shown to predict hospitalization and mortality.30 SES was 
assessed with the Socioeconomic Disadvantage Index (scored 0 to 3) which assigns one point 
each for low education (high school or less), unemployment, and low income reported as “just 
enough” or “not enough to make ends meet.”31 
RESULTS 
Prevalence and Comorbidity of SPADE Symptoms 
Table 1 shows the mean raw and T-scores of the PROMIS four-item measures for each 
of the five SPADE symptoms. Of the 250 patients, 80.8% had a pain T-score > 55 and thus met 
the operational threshold criteria for a potential clinically significant symptom. Furthermore, 
65.6% met the clinical threshold for fatigue, 52.8% for sleep disturbance, 37.2% for anxiety, and 
31.6% for depression.  The proportion of study patients exceeding the PROMIS pain score 
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threshold was less than 100% since eligibility for the SCOPE trial required endorsement of only 
a single BPI item (average or worst pain in the past week) as 5 or greater on a 0-10 scale, 
whereas the PROMIS score was derived from 4 items measuring pain interference, and the 
clinical threshold was set to be of a moderate level and comparable across all 5 symptoms.. 
Most patients had multiple symptoms; 9.6% (n = 24) of patients had no threshold symptoms, 
20% (n = 50) had one, 15.6% (n = 39) had two, 22.8% (n = 57) had three, 11.6% (n = 29) had 
four, and 20.4% (n = 51) reported having all five SPADE symptoms at or above threshold.  
Table 2 highlights the degree of clustering within each symptom subgroup where, as 
previously mentioned, a T-score of > 55 is operationally defined as a “clinical symptom.”  
Comorbidity of all symptoms was high in each symptom group. For example, of the 202 patients 
with threshold-level pain (i.e., T-score ≥ 55), the proportion with threshold-level fatigue, sleep 
disturbance, anxiety, and depression was 73.3%, 60.4%, 42.6%, and 37.5%, respectively. A 
similar degree of clustering was seen in each of the other four symptom groups. The clustering 
was also exemplified by the number of comorbid symptoms in each symptom group. For 
example, of the 202 patients with threshold-level pain, the proportion who had one, two, three, or 
all four of the other symptoms was 25.3%, 28.2%, 31.8%, and 13.9%, respectively. Indeed, for 
any given symptom, the likelihood of having no other symptoms was uncommon, ranging from 
7.6% to 12.9% in each of the five symptom groups. Thus, most patients were polysymptomatic 
rather than monosymptomatic. 
Reliability and Validity of the Composite Symptom Score 
The SPADE composite T-score had a mean of 54.8 (SD = 7.5) and a Cronbach’s alpha of 
0.86; 118 (47.2%) of the patients had a composite T-score ≥ 55. The SEM for the composite T-
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score was 2.84, suggesting that for an individual person a difference in the SPADE composite T-
score of 3 points or more might represent a clinically meaningful difference. 
Table 3 highlights the strong associations between both the composite and individual 
PROMIS symptom scale scores and all seven measures of construct validity. Among the 
PROMIS symptom measures, the composite score had the highest correlation with four of the 
construct validators (social functioning, general health, work effectiveness, and somatization) 
and the second highest correlation with two of the construct validators (mental component 
summary score and health-related disability days). With respect to sociodemographic factors, the 
composite symptom score was significantly worse (i.e., higher) for those with lower 
socioeconomic status (r2 = .323; p < .0001) and higher medical comorbidity (r2 = .224; p = 
.0004). Women also had a significantly higher mean composite PROMIS symptom score 
compared to men (58.0 vs. 54.1, p = .002). The composite score was not associated with age, 
race, or marital status. 
Somatic Symptom Burden as a Predictor of Functional Status Outcomes 
Table 4 shows that improvement in the composite symptom T-score is a significant 
predictor of improvement in five of the six functional status outcomes measured (i.e., all except 
work effectiveness).  Specifically, an antecedent improvement in symptom burden is 
significantly associated with better mental (MCS), physical (PCS) and social functioning, better 
self-rated general health, and fewer health-related disability days at subsequent points of follow-
up. The magnitude of improvement in terms of effect size ranged from 0.07 to 0.24, with the 
largest effect sizes for the mental component summary score (0.24), social functioning (0.22), 
and health-related disability days (0.18).  
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DISCUSSION  
Our study has three important findings. First, the SPADE symptoms commonly cluster, 
with the norm being a polysymptomatic patient, whereas only about 1 in 10 patients are 
monosymptomatic. Second, a composite SPADE symptom score demonstrates strong internal 
reliability as well as construct validity. Third, antecedent improvement in somatic symptom 
burden represented by a composite PROMIS SPADE score longitudinally predicts subsequent 
improvement in functional status at follow-up. 
Symptom cluster research initially focused on cancer patients;3, 4 however, a high co-
occurrence of symptoms seems to exist across a variety of diseases.1, 14 Although the five 
SPADE symptoms have not been specifically evaluated as one unique symptom cluster, much 
research has supported the existence of some of these symptoms as co-occurring in pairs (e.g., 
anxiety and depression or sleep and pain). Pain and depression co-occur with rates of 30-50%.11, 12 
In addition, many primary care patients seeking treatment for pain report significantly impaired 
sleep; which is known to aggravate pain and inflammatory processes, reduce endogenous pain 
inhibitory responses, and increase emotional distress and reduce well-being.13 Previous research 
has demonstrated the adverse effect that symptom clusters have on functional outcomes3, and our  
longitudinal analysis strengthens these findings by demonstrating that a reduction in SPADE 
symptom cluster severity predicts improvement in multiple functional outcomes.  
Our study provides preliminary data regarding use of the four-item PROMIS measures 
for sleep disturbance, pain, anxiety, depression, and fatigue to calculate a composite SPADE 
symptom score. Whereas individual symptom scores can be used to assess and monitor specific 
symptoms, the composite score may serve a complementary role in measuring and tracking 
overall symptom burden. Some treatments may be effective across multiple SPADE symptoms 
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(e.g., cognitive-behavioral therapy, exercise, certain types of antidepressants, self-management 
programs)1, 32 and may be considered for polysymptomatic patients as either primary or 
adjunctive therapies, particularly in individuals not responding to symptom-specific treatments. 
In such cases, tracking both individual and composite symptom scores may be useful in 
assessing clinical response and adjusting treatment.  Our study findings may also be useful in 
communicating with patients that clustering of symptoms is common, polypharmacy for 
concurrent symptoms (e.g., analgesics for pain, sedatives for sleep, psychostimulants for fatigue) 
may not always be the best approach, and monitoring response to treatment of one symptom may 
warrant attention to other symptoms as well. 
A statistical approach to estimating a minimally important clinical difference is the SEM, 
which was estimated to be approximately a 3-point change on the raw composite SPADE score 
in our sample. Because SEMs may vary among clinical populations, this 3-point estimate should 
be considered a preliminary finding. Furthermore, sensitivity to change with treatment may be an 
even better metric of responsiveness which requires testing changes in the PROMIS score in 
trials that target multiple SPADE symptoms. 
The finding that antecedent improvement in somatic symptom burden as measured by the 
PROMIS composite score predicts subsequent improvement in a number of functional status 
outcomes has important implications. The longitudinal nature of the MMRM analysis provides 
stronger evidence of a causal role for somatic symptoms influencing functional status. Also, it 
suggests that treatments effectively targeting SPADE symptoms may have beneficial effects on 
functional status and quality of life. Since pain, depressive, and anxiety disorders account for six 
of the nine most disabling chronic disorders from a population standpoint,10 our findings add to 
the public health importance of greater attention to common symptoms.  
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Three caveats regarding our finding that SPADE improvement predicts improvement in 
functional outcomes should be noted.  First, two of the measures in Table 4 (MCS and PCS) 
share several constructs in common with the SPADE composite score, in which case the 
predictive effect of SPADE improvement for MCS and PCS improvement may be overestimated 
due to shared variance.  However, the MCS and PCS also include constructs that are not captured 
by the SPADE composite score; moreover, the latter also predicted improvement in multiple 
outcomes in Table 4 with which it did not share any constructs.  Second, the effect sizes were 
larger for outcomes more influenced by mental (i.e., MCS and social functioning) than by 
physical (i.e., PCS) health. This may be because 2 of the 5 SPADE symptoms are depression and 
anxiety, or because symptoms in general have stronger effects on these outcomes. It is worth 
noting that there was also a moderate effect size for health-related disability, a construct not 
wedded specifically to mental or physical health.  Third, because our data was drawn from a 
clinical trial in which patients were randomized to either a treatment group or usual care group, 
some of the improvement in functional outcomes predicted by SPADE improvement may have 
been due in part to differential treatments in the clinical trial.  
Our study has several limitations. Although our sample was reasonably sized (N = 250), 
it was comprised of primary care patients with chronic musculoskeletal pain. Because PROMIS 
symptom scores may differ in non-pain or other clinical populations, our findings should be 
replicated in other samples. Second, our study enrolled predominantly male Veterans. Because 
women in our study and in other studies33, 34 typically have higher symptom scores, extending 
our research to samples including non-Veterans as well as more women is warranted. 
The use of PROMIS profiles and other standardized patient-reported outcome measures 
among researchers and clinical practitioners is well-aligned with initiatives set forth by the 
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National Institutes of Health,15, 16 and other groups35, 36 which seek to advance knowledge of 
symptom science and improve clinical outcomes among symptomatic patients. Additionally, 
determining the optimal way to display the scores to clinicians and patients as well as 
incorporating the scores into electronic medical records will facilitate future implementation.37, 38 
Furthermore, efficient and cost-effective systems-based strategies to facilitate the clinical 
management of symptoms in busy practice settings should be implemented since previous 
research has shown that simple feedback of scores alone may be inadequate to improve 
outcomes.1, 39 Finally, there has been a movement in recent years (further catalyzed by the 2011 
Institute of Medicine report) to view chronic pain not as merely a symptom, but rather as a 
chronic illness in and of itself.40 Measuring and addressing not only the cardinal symptom in 
patients with chronic pain but also the burdensome co-occurring symptoms has the potential of 
optimizing quality of life and other health outcomes. 
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Table 1. Baseline PROMIS SPADE Symptom Scores in 250 Primary Care Patients with 
Chronic Pain 
PROMIS 4-item scale Cronbach’s 
alpha 
Raw Score 
Mean (SD) 
T-score 
Mean (SD) 
T-score ≥ 55 
N (%) 
Pain 0.88 11.3 (4.2) 59.9   (7.1) 202 (80.8) 
Fatigue 0.93 12.4 (4.3) 57.2   (9.8) 164 (65.6) 
Sleep 0.88 12.7 (4.3) 55.4   (9.4) 132 (52.8) 
Anxiety 0.89 7.2 (3.7) 51.1 (10.1)   93 (37.2) 
Depression 0.93 7.0 (4.1) 50.2 (10.1)   79 (31.6) 
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Table 2. Clustering of SPADE Symptoms above Threshold (T-score ≥ 55) * 
 Pain Fatigue Sleep Anxiety Depression 
 (n =  202) (n =  164) (n = 132) (n = 93) (n = 79) 
Pain, n (%)  148 (90.2) 122 (92.4) 86 (92.5) 75 (94.9) 
Fatigue, n (%) 148 (73.3)  113 (85.6) 83 (89.3) 73 (92.4) 
Sleep, n (%) 122 (60.4) 113 (68.9)  66 (71.0) 57 (72.2) 
Anxiety, n (%) 86 (42.6) 83 (50.6) 66 (50.0)  71 (89.9) 
Depression, n (%) 75 (37.1) 73 (44.5) 57 (43.2) 71 (76.3)  
No. Comorbid 
Symptoms, n (%) 
     
0 22 (10.9) 17 (10.4) 17 (12.9) 9 (9.7) 6 (7.6) 
1 51 (25.3) 36 (22.0) 28 (21.2) 21 (22.6) 16 (20.3) 
2 57 (28.2) 48 (29.3) 35 (26.5) 27 (29.0) 22 (27.9) 
3 44 (21.8) 37 (22.6) 35 (26.5) 20 (21.5) 20 (25.3) 
4 28 (13.9) 26 (15.9) 17 (12.9) 16 (17.2) 15 (19.0) 
* Each symptom group is represented in a column and the totals of all 5 symptom groups 
exceeds 250 because of high co-occurrence rates. Proportions should be read down each column. 
For example, of the 202 patients with threshold-level pain, the proportion with fatigue, sleep, 
anxiety, and depression is 73.3%, 60.4%, 42.6%, and 37.1%, respectively. Likewise, the 
proportion with pain only, or 1, 2, 3, or 4 additional comorbid symptoms is 10.9%, 25.3%, 
28.2%, 21.8%, and 13.9%, respectively. 
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Table 3. Correlations Between PROMIS T-scores and Measures of Construct Validity 
Construct Validator 
Cron-
bach’s 
alpha* 
Correlations with PROMIS T-scores† 
SPADE 
Com-
posite 
Pain Fatigue Sleep Depress
ion 
Anxiety 
SF-12 Mental Component 0.90 -.785 -.517 -.552 -.445 -.821 -.761 
SF-12 Physical Component 0.90 -.417 -.610 -.456 -.332 -.186 -.172 
Social functioning, SF-36 0.85 -.702 -.662 -.595 -.430 -.588 -.559 
General health item, SF-12 n/a -.508 -.425 -.461 -.301 -.429 -.415 
Health-related disability days n/a .519 .549 .435 .391 .372 .369 
Work effectiveness, percent n/a -.473 -.372 -.366 -.288 -.433 -.427 
Somatization, PHQ-14 0.77 .681 .530 .629 .558 .512 .500 
* n/a = not applicable for this measure since it only consists of a single item or question 
† For all correlations that are negative, higher scores on the construct validator measure reflect 
better functioning or quality of life.  Thus, a negative correlation means that as the PROMIS 
symptom scores get higher (i.e., worse), the construct validator also gets worse (i.e., lower) 
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Table 4. Antecedent Change in Composite PROMIS SPADE T Score as a Predictor of 
Subsequent Functional Status Outcomes over 12 Months* 
Functional Status Outcome Beta 
coefficient 
(SE) 
P-
value 
Change in outcome per  
5-point improvement in 
PROMIS composite score 
Effect 
size † 
Mental component summary 
score (MCS), SF-12 
0.586  (.060) <.0001 2.9 point increased 
(improved) score 
0.24 
Social functioning, SF-36 1.200  (.151) <.0001 6.0 point increased 
(improved) score 
0.22 
Health-related disability days 
in past 4 weeks 
-0.302  (.053) <.0001 1.51 less disability days in 
past 4 weeks 
0.18 
Physical component 
summary score (PCS), SF-12 
0.172  (.053) .0014 0.9 point increased 
(improved) score 
0.10 
General health item, SF-12 0.534  (.148) .0004 2.7 point increased 
(improved) score 
0.09 
Percent work effectiveness  0.318  (.182) .083 1.6% increased (improved) 
score 
0.07 
* From mixed effects models for repeated measures (MMRM) with: (a) predictor variable being 
change in PROMIS composite score from baseline to 3 months and from 3 months to 12 months, 
(b) dependent variable being the functional status outcome, and (c) covariates adjusted for in the 
model being age, sex, medical comorbidity, and socioeconomic disadvantage index. 
† Effect size = change in outcome per 5-point improvement in PROMIS composite score divided 
by the standard deviation of the outcome at baseline.  
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